Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
08:00-08:30 | 08:00-08:30 |
Hepatology in Asia: 50 years and the future |
Masao OMATA | Yamanashi Central and Kita Hospitals, University of Tokyo |
08:30-09:00 | 08:30-09:00 |
Update on IgG4-related cholangitis (IRC) |
Jidong Jia | Beijing Friendship Hospital Capital Medical University |
09:00-09:30 | 09:00-09:30 |
CCIFLDI meets APASL: A history of first golden ten years |
Qin NING | Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
10:00-10:20 | 10:00-10:20 |
How to achieve WHO goal of HBV control? |
Jia-Horng Kao | National Taiwan University Hospital |
10:20-10:40 | 10:20-10:40 |
Clinical utility of new viral biomarkers for CHB |
Henry L.Y. Chan | The Chinese University of Hong Kong |
10:40-11:00 | 10:40-11:00 |
Stopping rules of NA therapy |
Di WU | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
11:00-11:20 | 11:00-11:20 |
Severe HBV flare with acute-on-chronic liver failure |
Man-Fung YUEN | The University of Hong Kong |
11:20-11:30 | 11:20-11:30 |
Panel Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
11:45-11:57 | 11:45-11:57 |
Difference between type 2 gastroesophageal varices and isolated fundic varices in clinical profiles and portosystemic collaterals |
Yuhu Song | Union Hospital, Tongji Medical College,Huazhong University of Science and Technology |
11:57-12:09 | 11:57-12:09 |
A low albumin to globulin ratio is a prognostic marker for bacterial infection in alcohol-related liver cirrhosis: a retrospective study |
Furong SUN | The First Hospital of China Medical University |
12:09-12:21 | 12:09-12:21 |
Clinical evaluation of bacterial DNA using an improved droplet digital PCR for the diagnosis of spontaneous bacterial peritonitis |
Haoxin WU | Capital medical university. Beijing youan hospital |
12:21-12:33 | 12:21-12:33 |
Research on Factors Linked with Occurrence of Minimal/Covert Hepatic Encephalopathy and Development of Overt Hepatic Encephalopathy |
Qiuyu CHENG | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
12:33-12:45 | 12:33-12:45 |
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Albumin in Cirrhotic Patients with Ascites |
Xinrui WANG | The first Hospital of Jilin University |
12:45-14:15 | 12:45-14:15 |
Mechanism-of-Action for Exosomes Derived from Human Adipose Mesenchymal Stem Cells in Liver Cirrhosis Treatment |
Zilong Zhang | Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
13:15-13:30 | 13:15-13:30 |
New pattern and new challenges, update of optimal strategies for chronic hepatitis B |
Zuojiong GONG | People's Hospital of Wuhan University |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
13:30-13:45 | 13:30-13:45 |
Clinical Cure Advances of Non-Active Hepatitis B's Antigen Carries (IHCs) |
Wei GUO | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
13:45-14:05 | 13:45-14:05 |
Management of acute and fulminant hepatitis B |
Sang Hoon AHN | Yonsei University College of Medicine |
14:05-14:25 | 14:05-14:25 |
A novel, long acting, interferon (Ropeginterferon) for chronic viral hepatitis B or D |
Pei-Jer CHEN | Hepatitis Research Center, National Taiwan University Hospital |
14:25-14:45 | 14:25-14:45 |
HBV and MAFLD: intriguing interactions |
Wai-Kay SETO | The University of Hong Kong |
14:45-15:05 | 14:45-15:05 |
Extension of treatment criteria in HBV |
Harry L.A. JANSSEN | University of Toronto and University Health Network |
15:05-15:15 | 15:05-15:15 |
Panel Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
15:30-16:00 | 15:30-16:00 |
Bacterial infections in patients with cirrhosis |
Paolo ANGELI | University of Padova |
16:00-16:30 | 16:00-16:30 |
Regulatory innate immune response in hepatitis B infection |
Zhenghong YUAN | Shanghai Public Health Clinical Center, Fudan University |
16:30-17:00 | 16:30-17:00 |
New treatment in management of chronic viral hepatitis B |
Man-Fung YUEN | The University of Hong Kong |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
17:00-17:20 | 17:00-17:20 |
HBV Cure Strategy |
Patricia MENDEZ / Christophe HEZODE | Gilead Science |
17:20-17:40 | 17:20-17:40 |
Functional cure strategy |
Xiaofei CHEN | Brii Bioscience |
17:40-18:00 | 17:40-18:00 |
Distribution and progress of liver diseases |
Dandan HUO | Chia Tai Tianqin |
18:00-18:30 | 18:00-18:30 |
Panel Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
18:30-18:45 | 18:30-18:45 |
Advantages of DPMAS in the treatment of HBV-ACLF |
Tao CHEN | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
18:45-19:00 | 18:45-19:00 |
Breakthrough、Innovation、Insight |
Peng HU | The Second Affiliated Hospital of Chongqing Medical University |